Merrimack Pharmaceuticals has announced the completion of enrollment of 27 patients into a Phase IIa study of the safety and efficacy of its immunomodulator, MM-093, in patients suffering from psoriasis. MM-093, Merrimack's lead product, is a recombinant version of human alpha-fetoprotein (AFP).
This study is a double-blind, placebo-controlled, randomized, outpatient clinical investigation in adult patients with moderate-to-severe chronic plaque psoriasis. Each patient receives double-blind treatment for 12 weeks, with a follow up period of six weeks after the last dose. The study is being conducted at the University of Utah inSalt Lake City.